Big Buttons

• FDA says tirzepatide shortage “resolved”

  As of this afternoon, the FDA Drug Shortage List is showing that the shortage of tirzepatide injection is “resolved.” Pharmacies must immediately cease preparing and dispensing compounded copies of Mounjaro and Zepbound. read more →

• Being a PFM just got better

  APC is launching five new benefits for our Pharmacy-Facility members to help you and your business prosper. read more →

• What’s in your liability policy?

  How good is your liability insurance? Do you know exactly what it covers (and how to check) so you aren’t in for a nasty surprise? read more →

• Thompson elected, Browning appointed

  Two changes to boards of directors were made last week. read more →

• Time to elect your 2025 APC board members

  Keep your eyes peeled for an important email: The ballot to vote for the 2025–26 APC Board of Directors. read more →

• HIPAA, schmipaa — Lilly is at it again

  Now Eli Lilly is trying to "convince" people who have used compounded versions of tirzepatide to share their confidential medical records with the company. read more →

• Settlement reached in Evexias suit against FDA

  A settlement has been reached in a lawsuit brought by Evexias et al against FDA over the agency's 2023 addition of a number of substances to Category 2 of the 503A bulks list. read more →

• Rochefort receives Malmberg Award

  David Rochefort of Revelation Pharma is this year's recipient of the George and Lucy Malmberg Compounding Advocacy Champion award — APC’s highest honor. read more →

More News

APC helped push back against the California Board of Pharmacy’s plan to all but outlaw glutathione, which has the potential to save the lives of firefighters. The board held off, and the Press-Democrat — which has had great coverage — quoted APC Chief Advocacy Officer Tenille Davis explaining how even the revised regulations “will dramatically increase costs, potentially to the point where some preparations become prohibitive to produce or access.”